Incyte Corporation (INCY) is expected to report first-quarter earnings on April 28, 2026. The Zacks Consensus Estimate for revenue is $1.23 billion, with earnings per share forecasted at $1.44. Jakafi (ruxolitinib), Incyte’s lead product, is projected to generate first-quarter sales of $742.8 million, contributing significantly to the company’s revenue.
For the same quarter, the projected sales for Opzelura are estimated at $162.9 million. Additionally, the anticipated first-quarter sales figures for Iclusig, Minjuvi/Monjuvi, and Pemazyre are $32.9 million, $42.8 million, and $22 million, respectively. Incyte’s earnings ESP stands at -17.11%, suggesting challenges to meet estimates, while its Zacks Rank is #3 (Hold).
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
